Skip to main content
Evidence Snapshot

Orexin/Hypocretin receptor type 1

CHEMBL2434819 SINGLE PROTEIN Mus musculus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:25:42Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2434819
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Orexin/Hypocretin receptor type 1 as ChEMBL target CHEMBL2434819, mapped to UniProt P58307. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Orexin/Hypocretin receptor type 1
SINGLE PROTEIN · Mus musculus
As of 2026-09-13
ChEMBL target ID
CHEMBL2434819
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P58307
Orexin/Hypocretin receptor type 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Orexin/Hypocretin receptor type 1 matters

As of 2026-09-13

Orexin/Hypocretin receptor type 1 is reviewed as Orexin/Hypocretin receptor type 1 (UniProt P58307); the current evidence base includes 1 approved drug, 5 compounds, and 3 assays, with lead potency reaching pChEMBL 8.8.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 1 approved drug, 5 compounds, and 3 assays for this target. The dominant activity type is KI. CHEMBL1083659 is the current potency anchor at pChEMBL 8.8.

Use CHEMBL1083659 as the tractability anchor when discussing potency (pChEMBL 8.8).

Activity source · ChEMBL 36 via Core Engine
1 approved pChEMBL 8.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Orexin/Hypocretin receptor type 1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P58307, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

5
Total Compounds
3
Total Assays
1
Approved Drugs
KI: 2.0, EC50: 2.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1083659
 8.8 Ki Approved
No preferred name
CHEMBL5417451
 6.8 EC50 —
No preferred name
CHEMBL5203887
 6.8 EC50 —
No preferred name
CHEMBL2435402
 6.3 Ki —

Approved Drugs

Structure Compound First Approval
SUVOREXANT
CHEMBL1083659
 2014
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:25:42Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2434819